In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei

Kate E Mounsey; Shelley F Walton; Ashlee Innes; Skye Cash-Deans; James S McCarthy

doi:10.1128/AAC.00381-17

In Vitro Efficacy of Moxidectin versus Ivermectin against Sarcoptes scabiei

Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00381-17. doi: 10.1128/AAC.00381-17. Print 2017 Aug.

Authors

Kate E Mounsey¹, Shelley F Walton², Ashlee Innes², Skye Cash-Deans², James S McCarthy^{3

4}

Affiliations

¹ Inflammation and Healing Cluster, School of Health & Sport Sciences, Faculty of Science, Health, Education, and Engineering, University of the Sunshine Coast, Sippy Downs, Australia kmounsey@usc.edu.au.
² Inflammation and Healing Cluster, School of Health & Sport Sciences, Faculty of Science, Health, Education, and Engineering, University of the Sunshine Coast, Sippy Downs, Australia.
³ QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
⁴ University of Queensland, Herston, QLD, Australia.

Abstract

Moxidectin is under consideration for development as a treatment for human scabies. As some arthropods show decreased sensitivity to moxidectin relative to ivermectin, it was important to assess this for Sarcoptes scabieiIn vitro assays showed that the concentration of moxidectin required to kill 50% of mites was lower than that of ivermectin (0.5 μM versus 1.8 μM at 24 h; P < 0.0001). This finding provides further support for moxidectin as a candidate for the treatment of human scabies.

Keywords: Sarcoptes scabiei; ivermectin; moxidectin; scabies; treatment.

Publication types

Comparative Study

MeSH terms

Acaricides / therapeutic use*
Animals
Female
Humans
Ivermectin / therapeutic use*
Macrolides / therapeutic use*
Male
Sarcoptes scabiei / drug effects*
Scabies / drug therapy*
Survival Analysis

Substances

Acaricides
Macrolides
Ivermectin
moxidectin